Barclays’s Rein Therapeutics RNTX Stock Holding History

Barclays’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.67K	Buy	+2,570	New	+$3.11K	﹤0.01%	4842
2021 Q4	–	Sell	-1,264	Closed	-$26K	–	4818
2021 Q3	$26K	Buy	1,264 +887	+235%	+$19.4K	﹤0.01%	4325
2021 Q2	$9K	Sell	377 -205	-35%	-$5.12K	﹤0.01%	4682
2021 Q1	$17K	Buy	+582	New	+$19.9K	﹤0.01%	4395
2019 Q4	–	Sell	-4	Closed	–	–	6887
2019 Q3	$0	Buy	+4	New	+$55	﹤0.01%	7203
2018 Q2	–	Sell	-57	Closed	-$9K	–	7351
2018 Q1	$9K	Buy	57 +27	+90%	+$4.81K	﹤0.01%	6695
2017 Q4	$6K	Buy	30 +24	+400%	+$5.75K	﹤0.01%	6646
2017 Q3	$2K	Buy	+6	New	+$1.5K	﹤0.01%	6698

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Barclays's RNTX Position: Q2 2026 in Review

Barclays opened a new position in Rein Therapeutics (RNTX) in Q2 2026: 2,570 shares worth $2.67K. The stake represents ﹤0.01% of the portfolio and ranks #4842 among its holdings. This is a return to the name: Barclays previously reported a position in RNTX as recently as Q3 2021.

Barclays first reported a position in RNTX in Q3 2017 and has held it in 8 quarters since. The position peaked at $26K in Q3 2021. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Barclays held 2,570 shares of Rein Therapeutics worth $2.67K as of Q2 2026.
Rein Therapeutics was a new Barclays position in Q2 2026.
Rein Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4842 holding.
Barclays first reported a position in Rein Therapeutics in Q3 2017 and has held it in 8 quarters since.
Barclays's Rein Therapeutics position peaked at $26K in Q3 2021.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.